Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

(2021) Kathryn A. Ryan et al.   Nature Communications

Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model

(2021) Can Li et al.   CLINICAL INFECTIOUS DISEASES

Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

(2021) Francisco J. Salguero et al.   Nature Communications

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

(2021) Kevin R. Bewley et al.   Nature Protocols

Status Report on COVID-19 Vaccines Development

(2021) Arun Kumar et al.   Current Infectious Disease Reports

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Isolation and rapid sharing of the 2019 novel coronavirus ( SARS ‐CoV‐2) from the first patient diagnosed with COVID ‐19 in Australia

(2020) Leon Caly et al.   MEDICAL JOURNAL OF AUSTRALIA

Developing Covid-19 Vaccines at Pandemic Speed

(2020) Nicole Lurie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid COVID-19 vaccine development

(2020) Barney S. Graham   SCIENCE

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

(2020) Meng Yuan et al.   SCIENCE

Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines

(2020) Paul-Henri Lambert et al.   VACCINE

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques

(2020) Neeltje van Doremalen et al.   Science Advances

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

(2020) Hui Wang et al.   CELL

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

(2020) Caroline Atyeo et al.   IMMUNITY

An Inactivated Virus Candidate Vaccine to Prevent COVID-19

(2020) Mark J. Mulligan   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

(2020) Neeltje van Doremalen et al.   NATURE

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

(2020) Ann M. Arvin et al.   NATURE

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

(2020) Daming Zhou et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

(2020) Kizzmekia S. Corbett et al.   NEW ENGLAND JOURNAL OF MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

(2020) Andrew D. Davidson et al.   Genome Medicine

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19

(2020) Benjamin J. Meckiff et al.   CELL

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Refinement and reduction through application of a quantitative score system for estimation of TB-induced disease burden using computed tomography

(2018) Sally A Sharpe et al.   LABORATORY ANIMALS

Role of PD-1 during effector CD8 T cell differentiation

(2018) Eunseon Ahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins

(2018) Torben Schiffner et al.   PLoS Pathogens

Viral-Induced Enhanced Disease Illness

(2018) Maria K. Smatti et al.   Frontiers in Microbiology

Antibody-dependent enhancement of severe dengue disease in humans

(2017) Leah C. Katzelnick et al.   SCIENCE

Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody

(2017) Katherine V. Houser et al.   PLoS Pathogens

Ferret hepatitis E virus infection induces acute hepatitis and persistent infection in ferrets

(2016) Tian-Cheng Li et al.   VETERINARY MICROBIOLOGY

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

(2016) Qidi Wang et al.   ACS Infectious Diseases

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

(2015) Patricio L. Acosta et al.   Clinical and Vaccine Immunology

Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens

(2015) Torben Schiffner et al.   JOURNAL OF VIROLOGY

Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env

(2015) Miklos Guttman et al.   Nature Communications

Advances in aluminum hydroxide-based adjuvant research and its mechanism

(2015) Peng He et al.   Human Vaccines & Immunotherapeutics

Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV

(2014) F. Yasui et al.   JOURNAL OF IMMUNOLOGY

Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine

(2014) N. Iwata-Yoshikawa et al.   JOURNAL OF VIROLOGY

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

(2012) Iris Delrue et al.   Expert Review of Vaccines

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

(2012) Chien-Te Tseng et al.   PLoS One

The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease

(2012) Christine A. Shaw et al.   VACCINE

Regulatory T Cells in Arterivirus and Coronavirus Infections: Do They Protect Against Disease or Enhance it?

(2012) Thomas E. Cecere et al.   Viruses-Basel

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

(2011) M. Bolles et al.   JOURNAL OF VIROLOGY

Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies

(2008) Jan Bonhoeffer et al.   VACCINE